Surf Therapeutics, Inc.

Based in the US, Surf Therapeutics, Inc. offers innovative solutions aimed at treating chronic inflammatory disorders through a non-invasive ultrasound neuromodulation platform. Surf Therapeutics, Inc. was founded in 2023 and is headquartered in Austin, US.

The company specializes in non-invasive ultrasound neuromodulation technology for chronic inflammatory conditions. In April 2026, Surf Therapeutics, Inc. raised an undisclosed amount of venture funding from new investor Xcellerant Ventures. .

Surf Therapeutics focuses on a pioneering non-invasive ultrasound neuromodulation platform specifically designed to treat chronic inflammatory disorders. Their core technology utilizes patented broad-beam ultrasound stimulation, which directs gentle acoustic energy into the body to activate the cholinergic anti-inflammatory pathway, engaging the nervous system to release neurotransmitters that help balance immune responses and aims to reduce uncontrolled inflammation. The primary end-users of these products include individuals suffering from autoimmune disorders such as rheumatoid arthritis, with a focus on providing innovative solutions in North America and Europe. Surf Therapeutics generates revenue through a direct-to-consumer model, where customers pay for access to its ultrasound neuromodulation devices and associated treatment plans.

The company’s flagship product is offered under a subscription model, providing regular updates and support. Revenue is further enhanced through partnerships with healthcare providers and clinics, facilitating patient engagement in managing chronic inflammatory conditions. The pricing is structured to ensure accessibility, aligning with the company's mission to transform treatment for inflammation. In April 2026, Surf Therapeutics, Inc.

raised an undisclosed amount of venture funding from new investor Xcellerant Ventures.